Rheumatoid Arthritis :: Enbrel safety data for up to 8 years in patients with juvenile rheumatoid arthritis
Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the presentation of additional data that showed that the safety profile of Enbrel? (etanercept) was maintained with long-term use in patients with moderate-to-severe juvenile rheumatoid arthritis (JRA) who completed up to eight years of therapy.